Himani Goyal, MD, John J. Chen, MD, PhD, and Mark P. Breazzano, MD, FACS, point to academic compensation, optic nerve damage, and who chooses retina.

OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

Timothy M. Janetos, MD, Donald J. D’Amico, MD, and Mark J. Gallardo, MD, point to uveitis access, clinical trial rigor, and procedural pharmaceuticals.

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

John A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.

John J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.